PharmaCyte Biotech, Inc. (PMCB)
NASDAQ: PMCB · Real-Time Price · USD
1.740
-0.090 (-4.92%)
Nov 4, 2024, 4:00 PM EST - Market closed
PharmaCyte Biotech Income Statement
Financials in millions USD. Fiscal year is May - April.
Millions USD. Fiscal year is May - Apr.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Jul '24 Jul 31, 2024 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 | Apr '21 Apr 30, 2021 | Apr '20 Apr 30, 2020 |
| Selling, General & Admin | 5.31 | 6.11 | 5.99 | 3.7 | 2.71 | 3.53 | |
| Research & Development | 0.4 | 0.41 | 0.47 | 0.69 | 0.92 | 0.3 | |
| Operating Expenses | 5.71 | 6.52 | 6.46 | 4.39 | 3.62 | 3.83 | |
| Operating Income | -5.71 | -6.52 | -6.46 | -4.39 | -3.62 | -3.83 | |
| Interest Expense | - | - | - | -0 | -0 | -0 | |
| Interest & Investment Income | 3.07 | 3.4 | 1.94 | 0.16 | - | - | |
| Other Non Operating Income (Expenses) | 9.46 | 5.45 | 0.2 | -0 | -0 | -0 | |
| EBT Excluding Unusual Items | 6.82 | 2.33 | -4.32 | -4.24 | -3.63 | -3.83 | |
| Asset Writedown | -2 | -2 | - | - | - | - | |
| Other Unusual Items | - | - | - | - | 0.08 | - | |
| Pretax Income | 26.94 | 0.33 | -4.32 | -4.24 | -3.55 | -3.83 | |
| Net Income | 26.94 | 0.33 | -4.32 | -4.24 | -3.55 | -3.83 | |
| Preferred Dividends & Other Adjustments | 22.44 | 17.57 | - | - | - | - | |
| Net Income to Common | 4.5 | -17.24 | -4.32 | -4.24 | -3.55 | -3.83 | |
| Shares Outstanding (Basic) | 8 | 10 | 19 | 16 | 1 | 1 | |
| Shares Outstanding (Diluted) | 8 | 10 | 19 | 16 | 1 | 1 | |
| Shares Change (YoY) | -51.83% | -50.84% | 25.56% | 971.73% | 60.24% | 23.23% | |
| EPS (Basic) | 0.54 | -1.80 | -0.22 | -0.27 | -2.45 | -4.23 | |
| EPS (Diluted) | 0.54 | -1.80 | -0.22 | -0.27 | -2.45 | -4.23 | |
| Free Cash Flow | -2.87 | -2.15 | -3.79 | -4.12 | -3.33 | -2.34 | |
| Free Cash Flow Per Share | -0.34 | -0.22 | -0.19 | -0.27 | -2.30 | -2.59 | |
| EBIT | -5.71 | -6.52 | -6.46 | -4.39 | -3.62 | -3.83 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.